This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies) represents the fourth time that Kalorama Information has taken a comprehensive look at oncology therapeutics. The report focuses on several segments for cancer treatment including:
One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. The report devotes particular attention to these new therapies.
This report, Kalorama's fourth complete research effort into the oncology treatments market in the past ten years, provides market size information for the various types of cancers including the following:
The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the industry.
As part of its coverage, the report looks at the following trends
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2010. Historical data was provided for the years 2005 through 2009, with forecast data provided for 2011 through 2015. Compound annual growth rates (CAGRs) are provided for the 2005-2010, 2010-2015 and 2005-2015 periods for each industry segment covered. Competitive analysis is provided for the year 2010. The forecasted market analysis for 2010-2015 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
Tyrosine kinase inhibitors such as Gleevac and Nexavar represent the fastest growing segment in the market for cancer treatments and have boosted the performance of many pharmaceutical companies, according to Kalorama Information. The healthcare market research publisher estimated the world market for cancer therapies to be $54.4 billion in 2010 in its latest report, The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition.
"Growth in cancer biotherapies spiked in the last five years, taking share from hormone and chemotherapy sales," said Bruce Carlson, publisher of Kalorama Information. "And within that category, tyrosine kinase inhibitors have demonstrated effectiveness and thus they've been growing fast in terms of sales."
Mutations in receptor tyrosine kinases cause cell proliferation and human disease. Drugs such as Iressa, Tarceva, Tykerb, Sprycel, Tasigna, Sutent and the segment's newest product Votrient, have been shown to inhibit the function of these receptors and thus mitigate the unusual cell growth that represents cancer. Sales will likely remain strong with research and development efforts focused on these newer therapies. In the last five years, Kalorama estimates that tyrosine kinase inhibitors grew by nearly 26.7%, faster than any other cancer treatment.
The report notes that a rising incidence of cancer, particularly in the over 50 population, is likely having a significant impact on all areas of cancer treatment. However, for many cancer types, there remains a significant unmet need in effective treatment. Lung cancer is one example, as patient survival is less than five years after diagnosis. The report covers new therapies that are in development.
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER FOUR: HORMONE THERAPY
CHAPTER FIVE: BIOTHERAPEUTICS
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
CHAPTER EIGHT: CORPORATE PROFILES
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook